<DOC>
	<DOCNO>NCT00052416</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth cancer stop blood flow tumor . PURPOSE : Phase I trial determine effectiveness thalidomide treat patient asymptomatic , indolent non-Hodgkin 's lymphoma chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Thalidomide Treating Patients With Asymptomatic , Indolent Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility , term toxicity patient compliance , thalidomide patient asymptomatic , indolent non-Hodgkin 's lymphoma chronic lymphocytic leukemia . - Determine event-free progression-free survival patient treated drug . - Determine disease response time next treatment patient treat drug . - Determine quality life patient treated drug . OUTLINE : Patients receive oral thalidomide daily . Treatment continue 18 month absence disease progression unacceptable toxicity . Quality life assess baseline , monthly study , end study . PROJECTED ACCRUAL : A total 30-36 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm indolent lymphoma leukemia one follow subtypes : Chronic lymphocytic leukemia Follicular center lymphoma ( grade I II ) Lymphoplasmacytic lymphoma Marginal zone lymphoma ( nodal , extranodal , splenic ) Small lymphocytic lymphoma Waldenstrom 's macroglobulinemia Any stage disease allow No hairy cell leukemia No Tcell lymphomas No prior treatment lymphoma/leukemia Considered appropriate expectant management Must require cytotoxic therapy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 Hemoglobin great 10.0 g/dL Platelet count great 75,000/mm^3 Hepatic Bilirubin great 2 time normal AST ALT great 2 time normal Renal Creatinine great 2.0 mg/dL Cardiovascular No uncontrolled congestive heart failure No New York Heart Association class III IV heart disease No unstable coronary artery disease No myocardial infarction past 6 month No serious uncontrolled arrhythmias No history thromboembolic disease Pulmonary No asthma chronic obstructive pulmonary disease require use home oxygen frequent oral steroid ( prednisone great 20 mg per day 5 day within past 3 month ) Other HIV negative Not pregnant nursing Negative pregnancy test Not plan become pregnant next 2 year Fertile female patient must use 1 highly effective method 1 additional effective method contraception 1 month prior , , 1 month study participation Male patient must use effective barrier contraception 1 month study participation Willing able participate S.T.E.P.S . ( System Thalidomide Education Prescribing Safety ) program No contraindication meeting requirement S.T.E.P.S . program No prior malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix No peripheral neuropathy No poorly control diabetes define either follow : Glycosylated hemoglobin great 8.0 g/dL Known end organ disease ( i.e. , nephropathy , retinopathy , neuropathy ) No concurrent illness would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>